

---

## New FDA Approved Indication for BRAFTOVI (encorafenib)

---

Dear Members,

Pfizer Oncology is proud to announce the FDA approval of BRAFTOVI® (encorafenib) in a new indication as part of a combination regimen. The following information is available for State Society review:

- BRAFTOVI [Full Prescribing Information](#) including Medication Guide

If you have any questions, please contact me at your earliest convenience. If you prefer not to receive emails like this one, please let me know and I will not send them to you in the future.

Sincerely,

Thanks,

**Allan Panka, MBA, CPC**

Field Reimbursement Manager, AZ, NM, CO, NV

Pfizer, Oncology

Office: [332-244-2356](tel:332-244-2356)

Cell: [619-300-9450](tel:619-300-9450)

[allan.panka@pfizer.com](mailto:allan.panka@pfizer.com)

*Pfizer is committed to complying with all applicable privacy laws, regulations, and company policies.*

*When communicating with us via email, please do not include any identifiable patient information such as patient names, birth dates, medical information, or any other patient identifying information. If you received this email message in error, please delete it and contact the sender.*